ESR1 and breast cancer: Because fulvestrant (pure estrogen receptor antagonist)-resistant breast cancer frequently shows the upregulation of mTOR pathway, the combination of fulvestrant and mTOR inhibitor is more efficious than fulvestrant alone [31].